Cancer Research Funding: Underfunded or Unequally Distributed?

Global cancer research funding is distributed unequally across disease types, geographic regions, treatment modalities, and research stages, according to recent analyses. While overall investments reach billions of dollars, highly lethal cancers, low-income nations, non-drug therapies, and clinical trials often receive a fraction of the resources allocated to discovery-phase biology and high-income institutions.

Cancer Research Funding and Disease Burden Imbalances

Cancer research funding does not consistently track with clinical mortality, according to a 2026 US analysis published in the JAMA Network. While breast cancer received approximately $1.58 billion in federal research funding during fiscal year 2025, prostate cancer received about $663 million, non–small cell lung cancer received $227 million, and small-cell lung cancer received $63 million. Combined, the two major lung cancer categories accounted for more than 151,000 estimated deaths, surpassing the mortality associated with either breast or prostate cancer.

Per-death funding calculations highlight these discrepancies even further. Breast cancer received roughly $69,800 per estimated death, and prostate cancer received about $126,992. Conversely, small-cell lung cancer received approximately $2,818 per death, non–small cell lung cancer received about $1,754, and pancreatic cancer received roughly $8,945, as reported in the 2026 Mohindroo analysis. Factors such as historical funding patterns, scientific opportunities, public awareness, and patient advocacy heavily shape these allocations.

Geographic Concentration and Low- and Middle-Income Country Underinvestment

Geographic disparities dictate where research dollars flow globally. Public and philanthropic organizations distributed approximately $51.4 billion through nearly 108,000 cancer research awards between 2016 and 2023, according to findings cited by Du et al. (2025), Pramesh et al. (2022), and Eldridge et al. (2025). High-income countries captured roughly 97% of this total investment.

Low-income countries received less than 0.1% of global funding, totaling about $8.4 million. The United States led contributors by providing roughly $29.3 billion, or 57% of the global total, followed by the United Kingdom, Japan, Australia, and Canada. This centralization leaves critical issues in low- and middle-income countries (LMICs)—such as late diagnosis, affordable treatment, and resource-adapted therapies—insufficiently studied, while oncology clinical trials remain scarce in those regions.

The Modality Divide: Disparities in Drugs, Surgery, and Radiotherapy

Treatment-focused research funding exhibits sharp divides across medical modalities, heavily favoring systemic drugs over procedural interventions. Global public and philanthropic analyses covering 2016 to 2020 show that drug-treatment research received approximately $4.6 billion, representing 19.6% of total investment, according to McIntosh et al. (2023) and Jairam et al. (2017). Radiotherapy received about $0.7 billion, or 2.8%, while surgery secured only $0.3 billion, or 1.4%.

Commercial sponsorship drives much of this disparity. An analysis of active phase III randomized oncology trials revealed that industry funding supported 48% of targeted-therapy trials and 32% of chemotherapy trials. By contrast, industry backed only 4% of radiotherapy trials and 5% of multimodality trials involving radiotherapy, leaving non-drug disciplines heavily reliant on limited public and academic budgets.

Imbalances Across Preclinical Research and Clinical Trials

Funding heavily tilts toward the earliest stages of scientific discovery rather than patient-facing evaluation. Preclinical laboratory research captured approximately 73.5% of global cancer research funding—about $18 billion—between 2016 and 2020, according to McIntosh et al. (2023). Phase 1 through 4 clinical trials received just 7.4%, or roughly $1.8 billion, while public-health research accounted for 9.4%.

An updated analysis spanning 2016 to 2023 confirmed this trend, finding that approximately 76% of funding ($39 billion) went to preclinical work, while clinical trials received about 7.3% ($3.7 billion). Implementation science, survivorship, and outcomes research receive comparatively limited support, creating hurdles in translating laboratory discoveries into routine clinical care.

Racial, Ethnic, and Advocacy-Driven Funding Disparities

Public visibility and fundraising capacity heavily influence financial support for specific malignancies. Nonprofits dedicated to breast cancer received about $460 million in 2015, accounting for one-third of all cancer-specific nonprofit revenue, according to Kamath et al. (2019) and Mutale et al. (2022). Leukemia, pediatric cancers, and lymphoma also drew substantial backing, whereas gastrointestinal, gynecologic, brain, and lung cancers lagged behind relative to their incidence.

These gaps intersect with demographic health disparities. Cancers that disproportionately affect Black populations in the United States—including colorectal, liver, and uterine cancers—often receive limited federal support. Furthermore, Black investigators have historically received major National Institutes of Health research grants at lower rates than White investigators, limiting the development of evidence addressing underserved populations.

Policy Shifts and Federal Grantmaking Rules

Frequently Asked Questions

Is cancer research underfunded?

In certain domains, yes. However, experts note that the primary challenge is unequal distribution across cancer types, geographic regions, treatment modalities, and research stages rather than a uniform lack of capital.

Which cancers receive the most research funding?

Breast cancer, prostate cancer, and blood cancers typically secure higher funding levels, bolstered by established research networks, public awareness campaigns, and dedicated advocacy groups.

Which cancers are commonly underfunded?

Highly lethal malignancies such as lung, pancreatic, liver, stomach, esophageal, bladder, and uterine cancers frequently receive less financial support relative to their mortality rates and years of life lost.

Why does drug research receive more funding than surgery or radiotherapy?

Drug development attracts substantial commercial investment because successful pharmaceutical therapies can be patented and marketed. Conversely, surgery and radiotherapy rely primarily on public and academic funding sources.

Why do low- and middle-income countries receive less funding?

Many LMICs face limitations in research infrastructure, local funding organizations, and capacity to lead large-scale clinical trials, which perpetuates a cycle of continued underinvestment.

How can cancer research funding become more equitable?

A balanced funding model would weigh mortality rates, years of life lost, geographic need, health disparities, and neglected areas like prevention and radiotherapy alongside traditional metrics.